1. Home
  2. BIIB vs BEKE Comparison

BIIB vs BEKE Comparison

Compare BIIB & BEKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$174.28

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

BEKE

KE Holdings Inc (each representing three)

HOLD

Current Price

$17.34

Market Cap

18.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIIB
BEKE
Founded
1978
2001
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
24.2B
18.8B
IPO Year
1991
2020

Fundamental Metrics

Financial Performance
Metric
BIIB
BEKE
Price
$174.28
$17.34
Analyst Decision
Buy
Strong Buy
Analyst Count
22
5
Target Price
$177.40
$24.36
AVG Volume (30 Days)
2.0M
4.7M
Earning Date
10-30-2025
11-10-2025
Dividend Yield
N/A
2.08%
EPS Growth
N/A
N/A
EPS
10.97
0.42
Revenue
$10,065,900,000.00
$14,540,474,652.00
Revenue This Year
$3.61
$7.14
Revenue Next Year
N/A
$4.90
P/E Ratio
$15.86
$41.41
Revenue Growth
4.77
25.42
52 Week Low
$110.04
$15.39
52 Week High
$185.17
$25.17

Technical Indicators

Market Signals
Indicator
BIIB
BEKE
Relative Strength Index (RSI) 55.41 53.64
Support Level $169.24 $16.14
Resistance Level $180.79 $17.66
Average True Range (ATR) 5.36 0.31
MACD -1.56 0.09
Stochastic Oscillator 33.70 80.00

Price Performance

Historical Comparison
BIIB
BEKE

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

About BEKE KE Holdings Inc (each representing three)

KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies, including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2024, Beike's co-founders collectively control the company, while Tencent and its affiliates share 8% of voting power.

Share on Social Networks: